Related Experiment Videos
Ankyloblepharon associated with systemic 5-fluorouracil treatment
1LSU Eye Center, Louisiana State University Medical Center School of Medicine, New Orleans 70112.
Annals of Ophthalmology
|October 1, 1987
Summary
Systemic 5-fluorouracil chemotherapy can cause severe ocular side effects, including conjunctival ulcers and blepharitis. Ophthalmologists must recognize these chemotherapy-induced ocular complications for timely intervention.
Area of Science:
- Ophthalmology
- Oncology
- Medical Science
Background:
- Metastatic adenocarcinoma of the stomach requires systemic chemotherapy.
- 5-fluorouracil (5-FU) is a common chemotherapeutic agent used for gastric cancer.
Observation:
- A 59-year-old male patient developed ocular lesions during 5-FU treatment.
- The lesions included bilateral conjunctival ulcers and ulcerative blepharitis.
- These conditions led to ankyloblepharon, a complication where eyelids fuse.
Findings:
- Chemotherapy, specifically 5-fluorouracil, can induce significant ocular toxicity.
- Ocular side effects manifest as inflammatory and ulcerative conditions of the conjunctiva and eyelids.
- Ankyloblepharon is a potential severe outcome of these ulcerative processes.
Implications:
- Ophthalmologists need to be aware of potential ocular adverse events associated with systemic chemotherapy.
- Early recognition of chemotherapy-induced ocular surface disease is crucial.
- Management may require adjustments to chemotherapy regimens or supportive ophthalmic care to prevent vision-threatening complications.